The termination of the Lilly collaboration and failure of the lead partnered program removes a key value driver and validation signal. Monitor for potential further pipeline attrition or need for additional financing if wholly owned programs fail to reach clinical milestones before the extended cash runway ends in H2 2029.
Price Chart
Executive Summary
Foghorn Therapeutics is discontinuing its Phase 1 trial of FHD-909 (SMARCA2 degrader) and the broader collaboration with Eli Lilly after the drug failed to show sufficient efficacy. The company is cutting ~40% of its workforce (~65 remaining employees) and shifting focus to wholly owned preclinical programs (EP300 degrader, immunology/inflammation, CBP degrader, induced proximity platform). The restructuring is expected to extend cash runway into H2 2029 but represents a major pipeline setback and loss of a partnered program.
Key Facts
- FHD-909 (LY4050784) Phase 1 dose escalation trial will not advance to expansion phase due to insufficient efficacy; the SMARCA2/4 synthetic lethality biology did not translate clinically.
- The collaboration with Eli Lilly on the Selective SMARCA2 degrader program is also terminated; no further collaboration activities are anticipated.
- Board approved a ~40% workforce reduction on September 30, 2026, expected to be substantially completed in Q4 2026, leaving ~65 full-time employees.
- Estimated restructuring charges of approximately $2.3 million, all cash expenditures for severance and benefits in Q4 2026.
- Cash runway extended into the second half of 2029 as a result of the pipeline prioritization and organizational changes.
- Company will focus on wholly owned programs: selective EP300 degrader, novel oral immunology/inflammation asset, selective CBP degrader, and induced proximity platform.
Financial Impact
Restructuring charges of ~$2.3 million in Q4 2026; cash runway extended into H2 2029; loss of partnered program revenue and milestone potential from Lilly collaboration.
Risk Factors
- Loss of partnered program revenue and validation from Eli Lilly collaboration.
- Wholly owned pipeline (EP300 degrader, CBP degrader, immunology/inflammation) is preclinical with no clinical data — high execution risk.
- Workforce reduction may impair ability to advance remaining programs.
- Potential need for dilutive financing if preclinical programs require more capital than anticipated.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-064102 |
| Exhibit: exhibit991foghornpressrele.htm | 0001628280-26-064102 |
| Document: 0001628280-26-064102-index-headers.html | 0001628280-26-064102 |
| Document: 0001628280-26-064102-index.html | 0001628280-26-064102 |
| Document: 0001628280-26-064102.txt | 0001628280-26-064102 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 21d ago | 3 | $1.97 $1.85 | ▼ −6.09% | ▼ −5.95% | $2.05 (+4.06%) |
Oct 5, 2026 21d ago | SC 13G/A | $1.97 $1.85 | ▼ −6.09% | ▼ −5.95% | $2.05 (+4.06%) |
Oct 1, 2026 26d ago | 8-K | $2.92 $1.99 | ▲ +31.85% | ▲ +33.15% | $2.05 (+29.79%) |
Aug 6, 2026 11w ago | 8-K | $5.57 $6.49 | ▲ +16.52% | ▲ +15.30% | $2.05 (−63.20%) |
May 7, 2026 24w ago | 8-K | $4.20 $4.17 | ▼ −0.71% | ▼ −2.22% | $2.05 (−51.19%) |
Apr 21, 2026 26w ago | Press Release | $5.39 $4.90 | ▼ −9.09% | ▼ −9.15% | $2.05 (−61.97%) |
Apr 21, 2026 27w ago | 8-K | $5.39 $4.90 | ▼ −9.09% | ▼ −9.15% | $2.05 (−61.97%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers